Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an update.
Shanghai Haohai Biological Technology Co., Ltd. has announced that its board of directors will meet on April 25, 2025, to review and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company focuses on developing and providing biological products and technologies.
YTD Price Performance: -9.94%
Average Trading Volume: 535,284
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$12.02B
See more data about 6826 stock on TipRanks’ Stock Analysis page.